Hybio Pharmaceutical Co., Ltd.

300199

CNE1000011T7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
12.2 ^CNY	+3.13%		-3.40%	-10.16%

Apr. 26	Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023

August 14, 2023 at 06:16 am EDT

Hybio Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 306.83 million compared to CNY 353.04 million a year ago. Revenue was CNY 325.28 million compared to CNY 356.53 million a year ago.

Net loss was CNY 34.13 million compared to CNY 98.22 million a year ago. Basic loss per share from continuing operations was CNY 0.04 compared to CNY 0.11 a year ago. Diluted loss per share from continuing operations was CNY 0.04 compared to CNY 0.11 a year ago.

Latest news about Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	Apr. 25	MT
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	Apr. 18	MT
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	Dec. 06	MT
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	Nov. 06	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	23-09-21	MT
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	23-09-21	MT
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index	23-09-18	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding	23-08-10	CI
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	23-07-12	MT
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	23-07-11	MT
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	23-05-17	MT
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.	23-04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	23-03-27	CI
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial	23-02-28	MT
Li Xiulan agreed to acquire a 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin for approximately CNY 450 million.	23-02-13	CI
Hybio Pharma's Controlling Shareholder and Party Acting in Concert Plan to Unload Stake	23-02-13	CI
Hybio Pharma Registers New Pen Injector Medical Device	23-01-22	MT
Hybio Pharmaceutical Sees Loss of Up to 380 Million Yuan for 2022	23-01-18	MT
Hybio Pharmaceutical Gets Regulatory Nod for Diabetes Drug; Shares Drop 5%	23-01-16	MT

Chart Hybio Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Companyâs products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HYBIO PHARMACEUTICAL CO., LTD.	-10.16%	1.49B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals